However, in-depth analyses indicate that clinical benefits are limited in patients with low PD-L1 expression, and treatment-related toxicity—such as immune-related pneumonia, hepatitis, and chemotherapy-induced myelosuppression—is increased (13). The gene discussed is CD274; the disease is Hepatitis.